AIM:To investigate the therapeutic effect of radical treatment and palliative treatment in stage Ⅳ pancreatic cancer patients.METHODS:81 patients were enrolled in the study.Radical treatment was performed on 51 patie...AIM:To investigate the therapeutic effect of radical treatment and palliative treatment in stage Ⅳ pancreatic cancer patients.METHODS:81 patients were enrolled in the study.Radical treatment was performed on 51 patients,while 30 patients were put under palliative treatment.The procedural safety and interval survival for stage Ⅳ pancreatic cancer(IS-Ⅳ) was assessed by almost 2.5 years of follow-ups.The IS-Ⅳ of patients under the two kinds of treatment,and the effects of treatment timing and frequency on IS-Ⅳ,were compared.RESULTS:The IS-Ⅳ of patients who received radical treatment was significantly longer than those who received palliative treatment(P < 0.001).The IS-Ⅳ of patients who received delayed radical or palliative treatment was longer than those who received accordingly timely treatment(P = 0.0034 and 0.0415,respectively).Multiple treatments can play an important role in improving the IS-Ⅳ of patients who received radical treatment(P = 0.0389),but not for those who received palliative treatment(P = 0.99).CONCLUSION:The effect of radical treatment was significantly more obvious than that of palliative treatment,and multiple radical treatments may contribute more to patients than a single radical treatment.展开更多
AIM To assess the clinical significance of prophylactic lateral pelvic lymph node dissection (LPLND) in stage Ⅳ low rectal cancer.METHODS We selected 71 consecutive stage Ⅳ low rectal cancer patients who underwent p...AIM To assess the clinical significance of prophylactic lateral pelvic lymph node dissection (LPLND) in stage Ⅳ low rectal cancer.METHODS We selected 71 consecutive stage Ⅳ low rectal cancer patients who underwent primary tumor resection,and enrolled 50 of these 71 patients without clinical LPLN metastasis.The patients had distant metastasis such as liver,lung,peritoneum,and paraaortic LN.Clinical LPLN metastasis was defined as LN with a maximum diameter of 10 mm or more on preoperative pelvic computed tomography scan.All patients underwent primary tumor resection,27 patients underwent total mesorectal excision(TME) with LPLND(LPLND group),and 23 patients underwent only TME(TME group).Bilateral LPLND was performed simultaneously with primary tumor resection in LPLND group.R0 resection of both primary and metastatic sites was achieved in 20 of 50 patients.We evaluated possible prognostic factors for 5-year overall survival (OS),and compared 5-year cumulative local recurrence between the LPLND and TME groups.RESULTS For OS,univariate analyses revealed no significant benefit in the LPLND compared with the TME group (28.7% vs 17.0%,P = 0.523); multivariate analysis revealed that R0 resection was an independent prognostic factor.Regarding cumulative local recurrence,the LPLND group showed no significant benefit compared with TME group (21.4% vs 14.8%,P = 0.833).CONCLUSION Prophylactic LPLND shows no oncological benefits in patients with Stage Ⅳ low rectal cancer without clinical LPLN metastasis.展开更多
Stage Ⅳ breast cancer refers to breast cancer that has already metastasized to distant regions when initially diagnosed. Treatment for stage Ⅳ is intended to "prolong survival and palliate symptoms". Resec...Stage Ⅳ breast cancer refers to breast cancer that has already metastasized to distant regions when initially diagnosed. Treatment for stage Ⅳ is intended to "prolong survival and palliate symptoms". Resection of a primary tumor is considered to be "effective only at alleviating chest symptoms and providing local control" in spite of the advances of imaging examination and medication for breast cancer. Molecular target and endocrine drugs are very effective and useful to tailor-make a treatment strategy according to breast cancer subtypes. Positron emission tomography-computed tomography can detect and diagnose the very small metastases and recurrences which can potentially be cured even if they are distant metastases. Recently, many retrospective studies have reported the survival benefit of surgery for breast cancer patients with metastases and some clinical trials which confirm the surgical prognostic benefit for them have started to enrol patients. The goal of treatment has to be clearly identified:increase the patient's survival time, provide local control or perform histology to determine the cancer's properties. The best evidence is absolutely essential to treat patients who need surgery at the right time. We need to evaluate the treatment strategy, including primary resection for stage Ⅳ breastcancer particularly, and find new evidence by prospective analysis.展开更多
Objective: To observe and compare the effect of traditional Chinese medicine (TCM) combined with chemotherapy (CT) on immune function and quality of life (QOL)of patients with non-small cell lung cancer (NSCLC) in sta...Objective: To observe and compare the effect of traditional Chinese medicine (TCM) combined with chemotherapy (CT) on immune function and quality of life (QOL)of patients with non-small cell lung cancer (NSCLC) in stage Ⅲ-Ⅳ. Methods: One hundred cases with stage Ⅲ-Ⅳ NSCLC were randomly divided into two groups. The treated group (n=50) received CT combined with TCM, and the control group received CT alone. The percentage of T lymphocyte subset in peripheral blood and the change of natural killer (NK) cell count were observed after treatment. The QOL and tolerance of CT were also compared between the two groups after treatment. Results: In the treated group, CD3 cell count, CD4 cell count, CD4/ CDg ratio and NK cell activity were higher than those in control group, while CD8 cell count in the treated group was lower than that in the control group (P<0.05), and QOL and tolerance of CT in the treated group were also better (P<0.05). Conclusion: TCM combined with CT could raise the patients' ability in tolerating CT in stage Ⅲ-ⅣNSCLC.展开更多
Objectice: Traditional Chinese medicine has a long history of over 2, 000 years in treating piles,based on the principle 'Sore herbs can be stringent while the puckery can control prolapse', and a large amount...Objectice: Traditional Chinese medicine has a long history of over 2, 000 years in treating piles,based on the principle 'Sore herbs can be stringent while the puckery can control prolapse', and a large amount of precious experience has been accumulated. Methods: Prepared mainly with such effective compositions as gallnut (Galla Chinensis) and alum, Xiaozhiling (XZL) was applied in treating piles of stages Ⅲ and Ⅳ. Fourstep injections were given at (1 ) the branches of artery rectalis superior (ARS), (2) the submucosa, (3) the mucous lamina propria, and (4) the sinous veins. The injection obliterated the ARS and made piles sclerosed, atrophied and finally disappear. Results: From 1987 to 1996, piles of stages Ⅲ and Ⅳ were treated of 21, 361 cases. Of all the cases, 21, 148 (99 % ) were cured, 203 (0. 95% ) improved and 10 (0. 05% ) ineffective for whom surgery was used. Of the 620 cases who were followed up 3 years after treatment, it recurred in only 6 cases (prolapse, 1 % ). Conclusion: This method summarized a relatively ideal non-operative approach in the treatment of piles of stages Ⅲ and Ⅳ.展开更多
During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-...During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new"standards of care"are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease.展开更多
Background Prognosis varies among stageⅣcolorectal cancer(CRC).Our study aimed to build a robust prognostic nomogram for predicting overall survival(OS)of patients with stageⅣCRC in order to provide evidence for ind...Background Prognosis varies among stageⅣcolorectal cancer(CRC).Our study aimed to build a robust prognostic nomogram for predicting overall survival(OS)of patients with stageⅣCRC in order to provide evidence for individualized treatment.Method We collected the information of 16,283 patients with stageⅣCRC in the Surveillance,Epidemiology,and End Results(SEER)database and then randomized these patients in a ratio of 7:3 into a training cohort and an internal validation cohort.In addition,501 patients in the Sixth Affiliated Hospital of Sun Yat-sen University(Guangzhou,China)database were selected and used as an external validation cohort.Univariate and multivariate Cox analyses were used to screen out significant variables for nomogram establishment.The nomogram model was assessed using time-dependent receiveroperating characteristic curve(time-dependent ROC),concordance index(C-index),calibration curve,and decision curve analysis.Survival curves were plotted using the Kaplan–Meier method.Result The C-index of the nomogram for OS in the training,internal validation,and external validation cohorts were 0.737,0.727,and 0.655,respectively.ROC analysis and calibration curves pronounced robust discriminative ability of the model.Further,we divided the patients into a high-risk group and a low-risk group according to the nomogram.Corresponding Kaplan–Meier curves showed that the prediction of the nomogramwas consistent with the actual practice.Additionally,model comparisons and decision curve analysis proved that the nomogram for predicting prognosis was significantly superior to the tumor-node-metastasis(TNM)staging system.Conclusions We constructed a nomogram to predict OS of the stageⅣCRC and externally validate its generalization,which was superior to the TNM staging system.展开更多
Gastric cancer with distant metastases,such as para-aortic lymph node metastases,hepatic metastases,and peritoneal dissemination,is classified as stage IV.In this situation,cancer cells have formed micrometastases thr...Gastric cancer with distant metastases,such as para-aortic lymph node metastases,hepatic metastases,and peritoneal dissemination,is classified as stage IV.In this situation,cancer cells have formed micrometastases throughout the body;therefore,according to the algorithm of the Japanese guidelines,stage IV cancer is outside the indication for curative resection.Recent advances in some chemical agents have been remarkable,and some patients have survived for long periods even with stage IV gastric cancer.Thus,even in patients with stage IV gastric cancer,there is a possibility that gastrectomy as conversion surgery could play an important role in the treatment strategy.Gastrectomy as conversion therapy can be safely conducted without perioperative mortality and is considered a sufficiently acceptable treatment strategy.However,the significance of conversion surgery for stage IV gastric cancer remains controversial.In this review,we summarize the treatment strategies and outcomes of conversion surgery for stage IV gastric cancer.展开更多
基金Supported by The Hai Zhu District Scientific and Technologica Plan,No.2010-Y-27"Comprehensive Research of Pancreati Cancer Cryotherapy",Guangzhou,China
文摘AIM:To investigate the therapeutic effect of radical treatment and palliative treatment in stage Ⅳ pancreatic cancer patients.METHODS:81 patients were enrolled in the study.Radical treatment was performed on 51 patients,while 30 patients were put under palliative treatment.The procedural safety and interval survival for stage Ⅳ pancreatic cancer(IS-Ⅳ) was assessed by almost 2.5 years of follow-ups.The IS-Ⅳ of patients under the two kinds of treatment,and the effects of treatment timing and frequency on IS-Ⅳ,were compared.RESULTS:The IS-Ⅳ of patients who received radical treatment was significantly longer than those who received palliative treatment(P < 0.001).The IS-Ⅳ of patients who received delayed radical or palliative treatment was longer than those who received accordingly timely treatment(P = 0.0034 and 0.0415,respectively).Multiple treatments can play an important role in improving the IS-Ⅳ of patients who received radical treatment(P = 0.0389),but not for those who received palliative treatment(P = 0.99).CONCLUSION:The effect of radical treatment was significantly more obvious than that of palliative treatment,and multiple radical treatments may contribute more to patients than a single radical treatment.
文摘AIM To assess the clinical significance of prophylactic lateral pelvic lymph node dissection (LPLND) in stage Ⅳ low rectal cancer.METHODS We selected 71 consecutive stage Ⅳ low rectal cancer patients who underwent primary tumor resection,and enrolled 50 of these 71 patients without clinical LPLN metastasis.The patients had distant metastasis such as liver,lung,peritoneum,and paraaortic LN.Clinical LPLN metastasis was defined as LN with a maximum diameter of 10 mm or more on preoperative pelvic computed tomography scan.All patients underwent primary tumor resection,27 patients underwent total mesorectal excision(TME) with LPLND(LPLND group),and 23 patients underwent only TME(TME group).Bilateral LPLND was performed simultaneously with primary tumor resection in LPLND group.R0 resection of both primary and metastatic sites was achieved in 20 of 50 patients.We evaluated possible prognostic factors for 5-year overall survival (OS),and compared 5-year cumulative local recurrence between the LPLND and TME groups.RESULTS For OS,univariate analyses revealed no significant benefit in the LPLND compared with the TME group (28.7% vs 17.0%,P = 0.523); multivariate analysis revealed that R0 resection was an independent prognostic factor.Regarding cumulative local recurrence,the LPLND group showed no significant benefit compared with TME group (21.4% vs 14.8%,P = 0.833).CONCLUSION Prophylactic LPLND shows no oncological benefits in patients with Stage Ⅳ low rectal cancer without clinical LPLN metastasis.
文摘Stage Ⅳ breast cancer refers to breast cancer that has already metastasized to distant regions when initially diagnosed. Treatment for stage Ⅳ is intended to "prolong survival and palliate symptoms". Resection of a primary tumor is considered to be "effective only at alleviating chest symptoms and providing local control" in spite of the advances of imaging examination and medication for breast cancer. Molecular target and endocrine drugs are very effective and useful to tailor-make a treatment strategy according to breast cancer subtypes. Positron emission tomography-computed tomography can detect and diagnose the very small metastases and recurrences which can potentially be cured even if they are distant metastases. Recently, many retrospective studies have reported the survival benefit of surgery for breast cancer patients with metastases and some clinical trials which confirm the surgical prognostic benefit for them have started to enrol patients. The goal of treatment has to be clearly identified:increase the patient's survival time, provide local control or perform histology to determine the cancer's properties. The best evidence is absolutely essential to treat patients who need surgery at the right time. We need to evaluate the treatment strategy, including primary resection for stage Ⅳ breastcancer particularly, and find new evidence by prospective analysis.
文摘Objective: To observe and compare the effect of traditional Chinese medicine (TCM) combined with chemotherapy (CT) on immune function and quality of life (QOL)of patients with non-small cell lung cancer (NSCLC) in stage Ⅲ-Ⅳ. Methods: One hundred cases with stage Ⅲ-Ⅳ NSCLC were randomly divided into two groups. The treated group (n=50) received CT combined with TCM, and the control group received CT alone. The percentage of T lymphocyte subset in peripheral blood and the change of natural killer (NK) cell count were observed after treatment. The QOL and tolerance of CT were also compared between the two groups after treatment. Results: In the treated group, CD3 cell count, CD4 cell count, CD4/ CDg ratio and NK cell activity were higher than those in control group, while CD8 cell count in the treated group was lower than that in the control group (P<0.05), and QOL and tolerance of CT in the treated group were also better (P<0.05). Conclusion: TCM combined with CT could raise the patients' ability in tolerating CT in stage Ⅲ-ⅣNSCLC.
文摘Objectice: Traditional Chinese medicine has a long history of over 2, 000 years in treating piles,based on the principle 'Sore herbs can be stringent while the puckery can control prolapse', and a large amount of precious experience has been accumulated. Methods: Prepared mainly with such effective compositions as gallnut (Galla Chinensis) and alum, Xiaozhiling (XZL) was applied in treating piles of stages Ⅲ and Ⅳ. Fourstep injections were given at (1 ) the branches of artery rectalis superior (ARS), (2) the submucosa, (3) the mucous lamina propria, and (4) the sinous veins. The injection obliterated the ARS and made piles sclerosed, atrophied and finally disappear. Results: From 1987 to 1996, piles of stages Ⅲ and Ⅳ were treated of 21, 361 cases. Of all the cases, 21, 148 (99 % ) were cured, 203 (0. 95% ) improved and 10 (0. 05% ) ineffective for whom surgery was used. Of the 620 cases who were followed up 3 years after treatment, it recurred in only 6 cases (prolapse, 1 % ). Conclusion: This method summarized a relatively ideal non-operative approach in the treatment of piles of stages Ⅲ and Ⅳ.
文摘During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new"standards of care"are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease.
基金supported by the National Natural Science Foundation of China[no.81970482,X.S.H.]National Natural Science Foundation of China[no.82172561,X.S.H.]Guangdong Basic and Applied Basic Research Foundation[no.2019A1515011313,X.S.H.].
文摘Background Prognosis varies among stageⅣcolorectal cancer(CRC).Our study aimed to build a robust prognostic nomogram for predicting overall survival(OS)of patients with stageⅣCRC in order to provide evidence for individualized treatment.Method We collected the information of 16,283 patients with stageⅣCRC in the Surveillance,Epidemiology,and End Results(SEER)database and then randomized these patients in a ratio of 7:3 into a training cohort and an internal validation cohort.In addition,501 patients in the Sixth Affiliated Hospital of Sun Yat-sen University(Guangzhou,China)database were selected and used as an external validation cohort.Univariate and multivariate Cox analyses were used to screen out significant variables for nomogram establishment.The nomogram model was assessed using time-dependent receiveroperating characteristic curve(time-dependent ROC),concordance index(C-index),calibration curve,and decision curve analysis.Survival curves were plotted using the Kaplan–Meier method.Result The C-index of the nomogram for OS in the training,internal validation,and external validation cohorts were 0.737,0.727,and 0.655,respectively.ROC analysis and calibration curves pronounced robust discriminative ability of the model.Further,we divided the patients into a high-risk group and a low-risk group according to the nomogram.Corresponding Kaplan–Meier curves showed that the prediction of the nomogramwas consistent with the actual practice.Additionally,model comparisons and decision curve analysis proved that the nomogram for predicting prognosis was significantly superior to the tumor-node-metastasis(TNM)staging system.Conclusions We constructed a nomogram to predict OS of the stageⅣCRC and externally validate its generalization,which was superior to the TNM staging system.
文摘Gastric cancer with distant metastases,such as para-aortic lymph node metastases,hepatic metastases,and peritoneal dissemination,is classified as stage IV.In this situation,cancer cells have formed micrometastases throughout the body;therefore,according to the algorithm of the Japanese guidelines,stage IV cancer is outside the indication for curative resection.Recent advances in some chemical agents have been remarkable,and some patients have survived for long periods even with stage IV gastric cancer.Thus,even in patients with stage IV gastric cancer,there is a possibility that gastrectomy as conversion surgery could play an important role in the treatment strategy.Gastrectomy as conversion therapy can be safely conducted without perioperative mortality and is considered a sufficiently acceptable treatment strategy.However,the significance of conversion surgery for stage IV gastric cancer remains controversial.In this review,we summarize the treatment strategies and outcomes of conversion surgery for stage IV gastric cancer.
